SynthesisFrontiers in pediatrics2026
Prophylactic oral antibiotic use for the prevention of cholangitis after Kasai portoenterostomy in patients with biliary atresia: a systematic review and meta-analysis.
Synthesis in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cholangitis is one of the most common and serious complications following Kasai portoenterostomy (KP) in patients with biliary atresia (BA). There is heterogeneity in antibiotic usage protocols across centers, and the efficacy of prophylactic oral antibiotics in preventing cholangitis remains unclear. This study aimed to assess the efficacy of prophylactic oral antibiotics in preventing cholangitis after KP in patients with BA. Methods: A systematic review and meta-analysis were conducted, incorporating all eligible studies published or presented as abstracts from inception to July 6th, 2026. Inclusion criteria required original data comparing the incidence of cholangitis in BA patients who received prophylactic oral antibiotics after KP versus those who did not receive. The primary outcome was the incidence of cholangitis within the follow-up period. Secondary outcomes included the native liver survival (NLS) rate and jaundice clearance rate. Subgroup analysis was conducted in the incidence of cholangitis according to study design [randomized controlled trial (RCT) and retrospective cohort vs. cross-sectional]. The Cochrane Risk of Bias tool, Newcastle-Ottawa Scale (NOS), and NOS-xs were used to assess the risk of bias. Heterogeneity among studies was assessed by the chi-square test, and the random-effects model or the fixed-effects model was selected according to heterogeneity. Results: Six studies, comprising 516 BA patients, met eligibility criteria. No statistically significant difference was observed in the incidence of cholangitis between the antibiotics and non-antibiotics groups [56.91% (177/311) vs. 56.59% (116/205), Conclusion: Current evidence does not support the protective effect of prophylactic oral antibiotics against cholangitis following KP in BA. Further high-quality, prospective randomized controlled trials are warranted to clarify causality and optimize antibiotic stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.